IL6 and rheumatoid arthritis: For diseases where tocilizumab has been effective (rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome), systemic inflammation is a feature of the disease and IL-6 levels are elevated.